All > Down Syndrome

Near-Infrared Transcranial Photobiomodulation for Down Syndrome

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Down SyndromeNear-Infrared Transcranial Photobiomodulation - Device
Eligibility
18 - 30
All Sexes
What conditions do you have?
Select

Study Summary

This trial will help researchers understand if a transcranial photobiomodulation (tPBM) can improve neural oscillations for people with Down syndrome.

Eligible Conditions
  • Down Syndrome

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

1
Near Infrared Imaging
1
Cohort 2 -100mg panitumumab-IRDye800
1
Non-Dilated Refraction

Study Objectives

3 Primary · 0 Secondary · Reporting Duration: Baseline to Post-Treatment (~6 weeks)

Week 6
Change in Cambridge Neuropsychological Test Automated Battery
Change in EEG
Change in Wordless Picture Book/Probes Driven Discussion

Trial Safety

Safety Progress

1 of 3

Similar Trials

1
Near Infrared Imaging
1
Cohort 2 -100mg panitumumab-IRDye800
2
Non-Dilated Refraction

Trial Design

2 Treatment Groups

Near-Infrared Transcranial Photobiomodulation (tPBM-NIR)
1 of 2
Sham Transcranial Photobiomodulation (tPBM-Sham)
1 of 2

Experimental Treatment

Non-Treatment Group

23 Total Participants · 2 Treatment Groups

Primary Treatment: Near-Infrared Transcranial Photobiomodulation · Has Placebo Group · N/A

Near-Infrared Transcranial Photobiomodulation (tPBM-NIR)
Device
Experimental Group · 1 Intervention: Near-Infrared Transcranial Photobiomodulation · Intervention Types: Device
Sham Transcranial Photobiomodulation (tPBM-Sham)
Device
PlaceboComparator Group · 1 Intervention: Sham Transcranial Photobiomodulation · Intervention Types: Device

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: baseline to post-treatment (~6 weeks)

Who is running the clinical trial?

Massachusetts General HospitalLead Sponsor
2,703 Previous Clinical Trials
30,853,185 Total Patients Enrolled
3 Trials studying Down Syndrome
982 Patients Enrolled for Down Syndrome
Paolo Cassano, MD, PhDPrincipal InvestigatorMassachusetts General Hospital
2 Previous Clinical Trials
153 Total Patients Enrolled

Eligibility Criteria

Age 18 - 30 · All Participants · 2 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
A doctor diagnoses DS if they believe the person has Trisomy 21, which is a genetic disorder caused by having an extra copy of chromosome 21
References

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top